GERN Geron (GERN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000886744
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
134
13F, latest reported quarter
Geron insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for GERON CORP in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 55.9% of the 17,645 shares held after it.
- No other insider sold within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF FINANCIAL OFFICER ROBERTSON MICHELLE sold about $19.1K of GERN on Feb 18, 2026, the largest insider sale at the company since 2024; 134 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 15, 2024.
- The trade is 100.0% of the 13,300 shares held after it.
- No other insider bought within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LAWLIS V BRYAN bought about $15.7K of GERN on May 9, 2025; 134 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 56.2% of the 26,682 shares held after it.
- 2 other insiders bought within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Officer Samuels Scott Alan bought about $24.1K of GERN on Feb 27, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 134 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 4, 2024.
- The trade is 100.0% of the 12,500 shares held after it.
- 2 other insiders bought within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President and CEO SCARLETT JOHN A bought about $22.1K of GERN on Feb 27, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 134 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 100,000 shares held after it.
- 2 other insiders bought within 30 days.
- 134 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Commercial Officer Ziegler James bought about $160.0K of GERN on Feb 27, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 134 funds added in the latest 13F quarter.20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
134 funds bought in last quarter
more than 79% of Pharma & Biotech
Revenue
-60.2% year over year
below 83% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.3% of the float short (float per yahoo 2026-10-26) · 7.4 days to cover · settled 2026-09-30
more than 76% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch GERN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-5.7%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GERN: institutional holders (13F)
13F holdings, latest reported quarter
49,115,571 sh
$62.9M
42,809,751 sh
$54.8M
42,808,659 sh
$54.8M
35,856,671 sh
$45.9M
29,038,928 sh
$37.2M
Congress trades in GERN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GERN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
GERN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.5M position · as of 2026-07-31
1.5%
ALPS Medical Breakthroughs ETF
$825.3K position · as of 2026-05-31
0.5%
ClearBridge Small Cap Growth Fund
$8.1M position · as of 2026-07-31
0.4%
ClearBridge Variable Small Cap Growth Portfolio
$1.7M position · as of 2026-06-30
0.4%
Invesco NASDAQ Future Gen 200 ETF
$57.2K position · as of 2026-05-31
0.3%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$27.9M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 2
0 active
1
Phase 3
1 active
1
Not applicable
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · John Scarlett
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$6.2M
$15.3M
$4.7M
+123%
-7%
2023
$5.0M
$4.5M
$2.8M
+33%
-6%
2022
$3.0M
$5.9M
$1.4M
+52%
-10%
2021
$2.1M
$1.3M
$1.2M
-23%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 134 funds added last quarter. Each figure is a federal filing, dated the day it went public.
GERN financials
Revenue growth
-60.2%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM GERN
| FY Dec 2025 | n/a |
| FY Dec 2024 | $29.5M |
| FY Dec 2023 | $237.0K |
| FY Dec 2022 | $596.0K |
| FY Dec 2021 | $1.4M |
| Jun 2026 | $57.5M |
| Mar 2026 | $51.8M |
| Dec 2025 | n/a |
| Sep 2025 | $47.2M |
| Jun 2025 | $49.0M |
| Mar 2025 | $39.6M |
| Dec 2024 | n/a |
| Sep 2024 | $28.3M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM GERN
| FY Dec 2025 | n/a |
| FY Dec 2024 | -592.2% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -8,335% |
| Jun 2026 | -29.0% |
| Mar 2026 | -7.0% |
| Dec 2025 | n/a |
| Sep 2025 | -39.0% |
| Jun 2025 | -33.4% |
| Mar 2025 | -50.1% |
| Dec 2024 | n/a |
| Sep 2024 | -93.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$115.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM GERN
| FY Dec 2025 | -$111.7M |
| FY Dec 2024 | -$219.3M |
| FY Dec 2023 | -$168.6M |
| FY Dec 2022 | -$127.8M |
| FY Dec 2021 | -$95.8M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$43.8M |
| Sep 2024 | -$58.9M |
At each fiscal year end
Single quarter
Debt to equity
0.55x
long-term 2026-06-30 plus current 2025-03-31 (15 months older than the period end); equity 2026-06-30
Debt to equity GERN
| FY Dec 2025 | 0.53x |
| FY Dec 2024 | 0.42x |
| FY Dec 2023 | 0.33x |
| FY Dec 2022 | 0.64x |
| FY Dec 2021 | 0.39x |
| Jun 2026 | 0.55x |
| Mar 2026 | 0.52x |
| Dec 2025 | 0.53x |
| Sep 2025 | 0.48x |
| Jun 2025 | 0.46x |
| Mar 2025 | 0.44x |
| Dec 2024 | 0.42x |
| Sep 2024 | 0.29x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.95x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-03-31 (15 months older than the period end)
Cash flow to debt GERN
| FY Dec 2025 | -0.93x |
| FY Dec 2024 | -1.85x |
| FY Dec 2023 | -2.05x |
| FY Dec 2022 | -2.49x |
| FY Dec 2021 | -1.92x |
| Jun 2026 | -0.95x |
| Mar 2026 | -1.05x |
| Dec 2025 | -0.93x |
| Sep 2025 | -1.11x |
| Jun 2025 | -1.50x |
| Mar 2025 | -1.72x |
| Dec 2024 | -1.85x |
| Sep 2024 | -2.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-28.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity GERN
| FY Dec 2025 | -33.0% |
| FY Dec 2024 | -66.1% |
| FY Dec 2023 | -112.3% |
| FY Dec 2022 | -137.5% |
| FY Dec 2021 | -68.8% |
| Jun 2026 | -28.3% |
| Mar 2026 | -27.1% |
| Dec 2025 | -33.0% |
| Sep 2025 | -29.6% |
| Jun 2025 | -31.1% |
| Mar 2025 | -45.3% |
| Dec 2024 | -66.1% |
| Sep 2024 | -69.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-12.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GERN
| FY Dec 2025 | -14.3% |
| FY Dec 2024 | -35.3% |
| FY Dec 2023 | -63.0% |
| FY Dec 2022 | -68.1% |
| FY Dec 2021 | -46.7% |
| Jun 2026 | -12.6% |
| Mar 2026 | -12.3% |
| Dec 2025 | -14.3% |
| Sep 2025 | -15.8% |
| Jun 2025 | -17.5% |
| Mar 2025 | -26.6% |
| Dec 2024 | -35.3% |
| Sep 2024 | -46.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital GERN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-11.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GERN
| FY Dec 2025 | -14.2% |
| FY Dec 2024 | -43.9% |
| FY Dec 2023 | -97.0% |
| FY Dec 2022 | -94.1% |
| FY Dec 2021 | -54.2% |
| Jun 2026 | -11.0% |
| Mar 2026 | -10.8% |
| Dec 2025 | -14.2% |
| Sep 2025 | -16.0% |
| Jun 2025 | -18.5% |
| Mar 2025 | -31.3% |
| Dec 2024 | -43.9% |
| Sep 2024 | -66.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing GERN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$796.3M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2025-03-31 (15 months older than the period end), minus cash 2026-06-30
Enterprise value GERN
| FY Dec 2025 | $884.6M |
| FY Dec 2024 | $2.2B |
| FY Dec 2023 | $1.2B |
| FY Dec 2022 | $916.9M |
| FY Dec 2021 | $407.7M |
| Jun 2026 | $878.6M |
| Mar 2026 | $1.0B |
| Dec 2025 | $884.6M |
| Sep 2025 | $915.2M |
| Jun 2025 | $939.3M |
| Mar 2025 | $1.0B |
| Dec 2024 | $2.2B |
| Sep 2024 | $2.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-15.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield GERN
| FY Dec 2025 | -13.3% |
| FY Dec 2024 | -10.2% |
| FY Dec 2023 | -14.7% |
| FY Dec 2022 | -13.9% |
| FY Dec 2021 | -24.4% |
| Jun 2026 | -14.0% |
| Mar 2026 | -13.3% |
| Dec 2025 | -13.3% |
| Sep 2025 | -15.3% |
| Jun 2025 | -19.9% |
| Mar 2025 | -20.2% |
| Dec 2024 | -10.2% |
| Sep 2024 | -7.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing GERN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | n/a | $237.0K | $596.0K |
| Operating income | -$68.6M | -$173.7M | -$193.9M | -$138.6M |
| Net income | -$83.5M | -$174.6M | -$184.1M | -$141.9M |
| EPS (diluted) | -0.13 | -0.27 | -0.32 | -0.37 |
| Operating cash flow | -$111.0M | -$218.6M | -$167.7M | -$127.4M |
| Cash | $77.6M | $79.0M | $70.0M | $56.8M |
| Long-term debt | $119.5M | $118.5M | $35.1M | $30.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
GERN Stock Sonar score 5/7 axes
Find similar shapesCompareGERN ranks highest on institutional and government (79th percentile) and profitability (73rd), and lowest on growth (17th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
